NP_063938.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
55,756 Da
NCBI Official Full Name
cytochrome P450 26B1 isoform 1
NCBI Official Synonym Full Names
cytochrome P450, family 26, subfamily B, polypeptide 1
NCBI Official Synonym Symbols
RHFCA; CYP26A2; P450RAI2; P450RAI-2 [Similar Products]
NCBI Protein Information
cytochrome P450 26B1; retinoic acid-metabolizing cytochrome; cytochrome P450 retinoic acid-inactivating 2; cytochrome P450 retinoid metabolizing protein; cytochrome P450, subfamily XXVIB, polypeptide 1
UniProt Protein Name
Cytochrome P450 26B1
UniProt Synonym Protein Names
Cytochrome P450 26A2; Cytochrome P450 retinoic acid-inactivating 2; Cytochrome P450RAI-2; Retinoic acid-metabolizing cytochrome
UniProt Synonym Gene Names
UniProt Entry Name
CP26B_HUMAN
NCBI Summary for CYP26B1
This gene encodes a member of the cytochrome P450 superfamily. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The encoded protein is localized to the endoplasmic reticulum, and functions as a critical regulator of all-trans retinoic acid levels by the specific inactivation of all-trans retinoic acid to hydroxylated forms. Mutations in this gene are associated with radiohumeral fusions and other skeletal and craniofacial anomalies, and increased levels of the encoded protein are associated with atherosclerotic lesions. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2013]
UniProt Comments for CYP26B1
CYP26B1: Involved in the metabolism of retinoic acid (RA), rendering this classical morphogen inactive through oxidation. Involved in the specific inactivation of all-trans-retinoic acid (all-trans-RA), with a preference for the following substrates: all-trans-RA > 9-cis-RA > 13-cis-RA. Generates several hydroxylated forms of RA, including 4-OH-RA, 4-oxo-RA, and 18-OH- RA. Esential for postnatal survival. Plays a central role in germ cell development: acts by degrading RA in the developing testis, preventing STRA8 expression, thereby leading to delay of meiosis. Required for the maintenance of the undifferentiated state of male germ cells during embryonic development in Sertoli cells, inducing arrest in G0 phase of the cell cycle and preventing meiotic entry. Plays a role in skeletal development, both at the level of patterning and in the ossification of bone and the establishment of some synovial joints. Defects in CYP26B1 are the cause of radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA). A disease characterized by craniofacial malformations, occipital encephalocele, radiohumeral fusions, oligodactyly, advanced osseous maturation, and calvarial mineralization defects. Belongs to the cytochrome P450 family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: EC 1.14.-.-; Oxidoreductase; Cofactor and Vitamin Metabolism - retinol; Cell development/differentiation
Chromosomal Location of Human Ortholog: 2p13.2
Cellular Component: endoplasmic reticulum membrane; cytoplasm
Molecular Function: retinoic acid binding; iron ion binding; retinoic acid 4-hydroxylase activity; heme binding
Biological Process: retinoic acid receptor signaling pathway; negative regulation of retinoic acid receptor signaling pathway; tongue morphogenesis; vitamin metabolic process; xenobiotic metabolic process; spermatogenesis; cell fate determination; male meiosis; proximal/distal pattern formation; embryonic limb morphogenesis
Disease: Radiohumeral Fusions With Other Skeletal And Craniofacial Anomalies
Research Articles on CYP26B1
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with CYP26B1 elisa kit
Pathways associated with CYP26B1 elisa kit
Diseases associated with CYP26B1 elisa kit
Organs/Tissues associated with CYP26B1 elisa kit
|